U.S. Global Investors (USGI)’s Corcept Therapeutics CORT Stock Holding History

U.S. Global Investors (USGI)’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-55,260	Closed	-$657K	–	168
2020 Q1	$657K	Buy	+55,260	New	+$684K	0.18%	60
2019 Q2	–	Sell	-44,128	Closed	-$518K	–	183
2019 Q1	$518K	Sell	44,128 -10,982	-20%	-$136K	0.25%	92
2018 Q4	$736K	Sell	55,110 -10,911	-17%	-$144K	0.43%	70
2018 Q3	$926K	Sell	66,021 -28,979	-31%	-$405K	0.45%	68
2018 Q2	$1.49M	Buy	+95,000	New	+$1.65M	0.68%	39

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

U.S. Global Investors (USGI)'s CORT Position: Q2 2020 in Review

U.S. Global Investors (USGI) sold out of Corcept Therapeutics (CORT) in Q2 2020, closing a stake of 55,260 shares — an estimated $657K sold.

U.S. Global Investors (USGI) first reported a position in CORT in Q2 2018 and held it in 5 quarters. The position peaked at $1.49M in Q2 2018. 224 funds tracked by Wall St. Rank hold CORT as of Q2 2020.

U.S. Global Investors (USGI) reported no remaining Corcept Therapeutics position as of Q2 2020 after selling out during the quarter.
U.S. Global Investors (USGI) sold 55,260 Corcept Therapeutics shares in Q2 2020, an estimated $657K.
U.S. Global Investors (USGI) first reported a position in Corcept Therapeutics in Q2 2018 and held it in 5 quarters.
U.S. Global Investors (USGI)'s Corcept Therapeutics position peaked at $1.49M in Q2 2018.
224 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2020.

Based on U.S. Global Investors (USGI)'s 13F filing for Q2 2020, filed 14 Aug 2020.